Data alone does not change practice — it only becomes powerful when it is believed.
For science to translate into real-world impact, it needs more than regulatory approval or medical affairs endorsement. It must be trusted by the clinicians who use it — and by the expert voices they turn to for guidance.
This is where advocacy comes in. Done well, it builds confidence, drives adoption, and shapes behaviour. Done poorly, it leads to disengagement, missed opportunities, and underperformance.
Why Advocacy Falls Short
Many companies engage expert voices — whether key opinion leaders (KOLs), key external experts (KEEs), or digital opinion leaders (DOLs) — but few do it strategically. Too often, advocacy is bolted on at the last minute: a speaker bureau pulled together in haste, a recycled list of familiar names, or an advisory board without clear purpose.
The consequences are predictable: late engagement, conflicting messages between teams, minimal support for clinicians, and little follow-up or measurement. The result is advocacy that feels inconsistent, unconvincing — and ultimately ineffective.
Why Belief Matters as Much as Evidence
Even the most robust clinical data won’t change practice if it doesn’t inspire confidence. Both the expert voice and the listening clinician need to believe in the science — and feel motivated to act on it.
Without that belief, launches stall, uptake slows, brands lose their edge, and experts turn their attention elsewhere. Belief is the real driver of adoption, built through trusted voices, clear messaging, and the right timing.
The Cost of Getting It Wrong
Fragmented advocacy doesn’t just create frustration — it has measurable costs. Market penetration slows. Internal teams pull in different directions. Investments sink into low-impact activities. Relationships with experts fray. Compliance risks rise. Products never reach their full potential.
These are not soft losses. They directly erode revenue, time, and competitive advantage.
A Smarter Way Forward
At ArtiaCo., we help pharmaceutical and MedTech companies design advocacy strategies that are structured, scalable, and sustainable. Our approach is:
- Aligned to the product lifecycle, from pre-launch through post-market.
- Strategically segmented, so the right experts are engaged for the right reasons.
- Clinically credible and compliant, with FMV, contracting, and support in place.
- Cohesive across functions, ensuring medical, commercial, and marketing teams act as one.
- Supportive of clinicians, helping them engage with confidence and clarity.
When advocacy is designed this way, it becomes a long-term asset — not a last-minute expense.
Let’s Build Advocacy That Works
If you’re preparing for launch, managing complex expert relationships, or simply want more impact from your current programme, we can help.
At ArtiaCo., we make sure your science is not only seen and heard — but also trusted, adopted, and believed. If your advocacy programmes are built around the “usual suspects,” it may be time to rethink. Get in touch to see how we can help.
